Latest News

ACADIA Pharmaceuticals acquires CerSci Therapeutics, adds novel pain program to portfolio

August 25, 2020 | ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, including non-opioid therapies for acute and chronic pain. Under the terms of the agreement, ACADIA acquired all of the outstanding shares of CerSci for $52.5 million, primarily in ACADIA stock. The transaction closed on August 24, 2020. CerSci shareholders may also receive up to $887 million in development, commercialization, and sales milestones in addition to tiered royalties in the mid-single digits based on annual net sales.

Back to top

Baxter Healthcare Holds 2020 Q1 Analyst Call

April 30, 2020 | Alpha Street

Baxter Healthcare, the world leader in inhaled anesthesia, comments on its performance for the first quarter of 2020. In addition to reporting financial performance and ongoing plans, they make two important comments related to inhaled anesthesia. First, they announce declines of inhaled anesthesia sales in the first quarter and expected decreased sales in the second quarter all related to a decline in surgery due to COVID-19. Second, they note that their inhaled anesthesia products are among their higher-margin products. Third, they note that declines in financial performance from their Advanced Surgery portfolio (which contains inhaled anesthesia) have been and are expected to be offset by revenue and other gains elsewhere in their operations.

Back to top